Indigenously-developed Bharat Biotech's Covid-19 vaccine Covaxin neutralises multiple variants of SARS-CoV-2. Covaxin also effectively neutralises the double mutant strain as well, the Indian Council of Medical Research (ICMR) said today.
"ICMR study shows #COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well," ICMR said in a tweet.
ICMR-National Institute of Virology has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus: B.1.1.7 (the UK variant), B.1.1.28 (Brazil variant ) and B.1.351 (South Africa variant).
ICMR-NIV has demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variant, the apex health research body said.
ICMR-NIV recently has been successful in isolating and culturing the double mutant strain B.1.617 SARS-CoV-2 identified in certain regions of India and several other countries, the ICMR stated. "Covaxin has been found to effectively neutralise the double mutant strain as well," it said.
Meanwhile, Serum Institute of India (SII) has fixed the price of Covishield vaccine at ₹600 per dose for private hospitals and ₹400 per jab for state governments, the company said in a release.